“As we move forward, I am committed to ensuring that we put our collective efforts towards evaluating the potential of MICVO in a timely fashion,” said Thomas Civik, Interim Chief Executive Officer.

Pyxis Oncology has concluded its first multi-target sublicensing agreement under the new arrangement with a stealth ADC company. This expansion builds on the former agreement, which provided Pyxis ...

Pyxis Oncology needs to pave a longer cash runway. To do so, the Pfizer-partnered antibody-drug conjugate (ADC) biotech is cutting 40% of staff, slimming its programs and looking to monetize royalty ...

Lara Sullivan, Pyxis Oncology CEO, joins Yahoo Finance to discuss the biotech company going public and its oncology treatments for patients with difficult-to-treat cancer. JARED BLIKRE: Well, an IPO ...

Antibody drug conjugates, or ADCs, are picking up momentum. Of the 11 drugs in this class that have been approved by the FDA, six have reached the market in the last two years. Meanwhile, new ADC ...